1-6 of 6
Silke Gloaguen
Close
Sort by
Journal Articles

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Lionel Ades, Sophie Dimicoli-Salazar, Marie Sebert, Thomas Cluzeau, Aspasia Stamatoulas Bastard, Kamel Laribi, Gaelle Fossard, Raphael Itzykson, Odile Beyne Rauzy, Alice Garnier, Silke Gloaguen, Norbert Vey, Caroline Le Jeune, Aristoteles Giagounidis, Emmanuel Gyan, Baptiste Perard, Sylvain Thepot, Mario Ojeda, Fatiha Chermat, Kristell Desseaux, Emmanuelle Clappier, Sylvie Chevret, Uwe Platzbecker, Pierre Fenaux
Journal: Blood
Blood (2021) 138 (Supplement 1): 63.
https://doi.org/10.1182/blood-2021-147898
Published: 2021
Journal Articles

A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia

Anne Sophie Kubasch, Aristoteles Giagounidis, Georgia Metzgeroth, Anna Jonasova, MD PhD, Regina Herbst, MD, Jose Miguel Torregrosa Diaz, Benoit De Renzis, MD, Katharina S. Götze, Marie-Luise Huetter-Kroenke, MD, Marie-Pierre Gourin, Bohrane Slama, MD, Sophie Dimicoli-Salazar, MD, Pascale Cony-Makhoul, MD, Kamel Laribi, MD, Sophie Park, MD PhD, Katja Jersemann, Dorothea Schipp, Klaus H. Metzeler, MD, Oliver Tiebel, MD, Katja Sockel, MD, Silke Gloaguen, Msc, Anna Mies, Fatiha Chermat, Christian Thiede, MD, Rosa Sapena, Richard F. Schlenk, Pierre Fenaux, MD PhD, Uwe Platzbecker, Lionel Ades, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-139291
Published: 2020
Journal Articles

Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents

Anne Sophie Kubasch, Pierre Peterlin, MD, Thomas Cluzeau, MD PhD, Katharina S. Götze, Katja Sockel, MD, Raphael Teipel, MD, Madlen Jentzsch, MD, Sabine Kayser, MD, Habiba Attalah, Fatiha Chermat, Silke Gloaguen, Msc, Katja Jersemann, Dorothea Schipp, Aristoteles Giagounidis, Stuart McPherson, BSc, Irene Tirado-González, Arjan van de Loosdrecht, MD PhD, Pierre Fenaux, MD PhD, Uwe Platzbecker, Hind Medyouf, Lionel Ades, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-140240
Published: 2020
Journal Articles

Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial

Raphael Itzykson, MD PhD, Valeria Santini, Cendrine Chaffaut, Ades Lionel, Sylvain Thepot, MD, Aristoteles Giagounidis, Margot Morabito, Nathalie Droin, Michael Luebbert, Rosa Sapena, Stanislas Nimubona, MD, Jean E. Goasguen, MD PhD, Eric Wattel, MD PhD, Gina Zini, MDPhD, Jose Miguel Torregrosa Diaz, Ulrich Germing, Anna Maria Pelizzari, Sophie Park, MD PhD, Nadja Jaekel, Georgia Metzgeroth, Francesco Onida, MD, Robert Navarro, Andrea Patriarca, MD, Aspasia Stamatoulas Bastard, MD, Martin Puttrich, Sandra Mossuto, Eric Solary, MD PhD, Silke Gloaguen, Msc, Sylvie Chevret, MD PhD, Fatiha Chermat, Uwe Platzbecker, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 53–54.
https://doi.org/10.1182/blood-2020-138680
Published: 2020
Journal Articles

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Uwe Platzbecker, MD, Anne Sophie Kubasch, MD, Aristoteles Giagounidis, MD, Georgia Metzgeroth, Anna Jonasova, MD PhD, Regina Herbst, MD, Jose Miguel Torregrosa Diaz, Benoit De Renzis, MD, Katharina Götze, Marie-Luise Huetter-Kroenke, MD, Marie-Pierre Gourin, Borhane Slama, MD, Sophie Dimicoli-Salazar, MD, Pascale Cony-Makhoul, MD, Kamel Laribi, MD, Sophie Park, MD PhD, Katja Jersemann, Oliver Tiebel, MD, Katja Sockel, MD, Silke Gloaguen, MSc, Anna Mies, Fatiha Chermat, Christian Thiede, MD, Rosa Sapena, Richard F. Schlenk, MD, Pierre Fenaux, MD PhD, Lionel Ades, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2998.
https://doi.org/10.1182/blood-2019-129047
Published: 2019
Journal Articles

Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial

Anne Sophie Kubasch, MD, Freya Schulze, Katharina S. Götze, MD, Jan Krönke, MD, Katja Sockel, MD, Jan Moritz Middeke, MD, Fatiha Chermat, Silke Gloaguen, MSc, Martin Puttrich, Carmen Weigt, Katja Jersemann, Pierre Fenaux, MD PhD, Richard F. Schlenk, MD, Aristoteles Giagounidis, Lionel Ades, MD PhD, Anna Mies, Uta Oelschlaegel, Uwe Platzbecker
Journal: Blood
Blood (2018) 132 (Supplement 1): 4045.
https://doi.org/10.1182/blood-2018-99-113112
Published: 2018